Steven Cohen’s enGene Therapeutics ENGN Stock Holding History

Steven Cohen’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.2K	Sell	13,992 -159,399	-92%	-$650K	﹤0.01%	3862
2026 Q1	$1.18M	Sell	173,391 -388,406	-69%	-$3.46M	﹤0.01%	2658
2025 Q4	$5.07M	Sell	561,797 -646,602	-54%	-$5.18M	0.01%	1840
2025 Q3	$8.25M	Buy	1,208,399 +100	+0%	+$456	0.01%	876
2025 Q2	$4.4M	Sell	1,208,299 -32,889	-3%	-$123K	0.01%	1019
2025 Q1	$5.56M	Buy	1,241,188 +16,391	+1%	+$102K	0.01%	888
2024 Q4	$8.14M	Buy	1,224,797 +561,797	+85%	+$4.36M	0.02%	761
2024 Q3	$4.38M	Buy	663,000 +619,100	+1,410%	+$4.61M	0.01%	919
2024 Q2	$414K	Sell	43,900 -138,686	-76%	-$1.78M	﹤0.01%	1484
2024 Q1	$3.09M	Buy	+182,586	New	+$2.23M	0.01%	1120

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Steven Cohen's ENGN Position: Q2 2026 in Review

Steven Cohen reduced its enGene Therapeutics (ENGN) stake by 92% in Q2 2026, selling an estimated $650K and leaving 13,992 shares worth $24.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3862.

Steven Cohen first reported a position in ENGN in Q1 2024 and has held it in 10 quarters since. The position peaked at $8.25M in Q3 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

Steven Cohen held 13,992 shares of enGene Therapeutics worth $24.2K as of Q2 2026.
Steven Cohen sold 159,399 enGene Therapeutics shares in Q2 2026, an estimated $650K.
enGene Therapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #3862 holding.
Steven Cohen first reported a position in enGene Therapeutics in Q1 2024 and has held it in 10 quarters since.
Steven Cohen's enGene Therapeutics position peaked at $8.25M in Q3 2025.
60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.